Marginum
A university-based medical technology startup developing fluorescence-based tissue detection systems.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €2.5m | Seed | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Marginum is a Finnish medical technology startup specializing in advanced tissue recognition technology, particularly for oncological (cancer-related) surgeries. The company aims to revolutionize cancer surgery by providing innovative solutions that enhance the efficiency and safety of surgical procedures. Marginum's primary product is a fluorescence-based tissue detection system that helps surgeons accurately identify and differentiate between cancerous and healthy tissues during surgery. This technology is crucial for improving surgical outcomes and patient safety.
Marginum serves a diverse range of clients, including hospitals, surgical centers, and medical professionals involved in cancer treatment. The company operates in the medical technology market, focusing on surgical oncology—a field dedicated to the surgical treatment of cancer. With the global cancer incidence projected to increase by 55% by 2040, the demand for advanced surgical tools like those developed by Marginum is expected to grow significantly.
The business model of Marginum revolves around the development, manufacturing, and sale of its tissue monitoring solutions. The company generates revenue through the direct sale of its products to healthcare institutions and through partnerships with medical device distributors. Additionally, Marginum may explore opportunities for licensing its technology to other medical device manufacturers.
Marginum has recently raised significant funding to support its market entry and further development of its tissue sensing technology. The investment round was led by Almaral, Nostetta Ventures, and Redstone, with additional support from a Business Finland R&D loan. This financial backing underscores the confidence investors have in Marginum's potential to become a leading player in the medical technology sector.
The company's vision is to be the leading manufacturer of aspirate tissue monitoring solutions by 2028. Marginum's mission is to pioneer the next generation of surgical techniques, ensuring safe and efficient tissue monitoring without disrupting surgical workflows.
Keywords: tissue recognition, cancer surgery, fluorescence detection, medical technology, surgical oncology, patient safety, healthcare innovation, tissue monitoring, startup, Finland.